VERTEX PHARMACEUTICALS INC / MA Shareholders' Equity
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Shareholders' Equity of $20.25 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $20.25B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $19.36B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $18.67B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $17.32B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $20.25B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $19.36B 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $18.67B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $17.32B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $17.18B 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $16.50B 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $16.41B 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $15.63B 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $14.77B 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $18.55B 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $17.58B 10-K · filed 2026-02-13 | |
| 2023-09-30 | $16.51B 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $15.47B 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $14.43B 10-Q · filed 2024-08-02 | |
| 2022-12-31 | $13.91B 10-K · filed 2026-02-13 | |
| 2022-09-30 | $13.03B 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $11.93B 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $10.91B 10-Q · filed 2023-08-02 | |
| 2021-12-31 | $10.10B 10-K · filed 2025-02-13 | |
| 2021-09-30 | $9.53B 10-Q · filed 2022-10-28 | $9.53B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $9.20B 10-Q · filed 2022-10-28 | $9.20B 10-Q · filed 2021-07-30 |
| 2021-03-31 | $8.98B 10-Q · filed 2022-08-05 | $8.98B 10-Q · filed 2021-04-30 |
| 2020-12-31 | $8.69B 10-K · filed 2024-02-15 | $8.69B 10-Q · filed 2021-04-30 |
| 2020-09-30 | $8.13B 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $7.52B 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $6.46B 10-Q · filed 2021-07-30 | |
| 2019-12-31 | $6.09B 10-K · filed 2023-02-10 | $6.09B 10-Q · filed 2020-10-30 |
| 2019-09-30 | $5.25B 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $5.07B 10-Q · filed 2020-10-30 | |
| 2018-12-31 | $4.44B 10-K · filed 2022-02-09 | $4.44B 10-K · filed 2019-02-13 |
| 2018-09-30 | $2.91B 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $2.69B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $2.40B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $2.03B 10-K · filed 2019-02-13 | |
| 2017-09-30 | $1.79B 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $1.67B 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $1.50B 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $1.16B 10-K · filed 2018-02-15 | |
| 2016-09-30 | $1.02B 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $981.35M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $957.08M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $939.97M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $922.15M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $894.96M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $976.46M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $1.08B 10-K · filed 2016-02-16 | |
| 2014-09-30 | $1.16B 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $1.17B 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $1.23B 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $1.36B 10-K · filed 2015-02-13 | |
| 2013-09-30 | $1.26B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $1.32B 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $746.12M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $999.18M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $1.03B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $1.04B 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $930.50M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $786.84M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $579.76M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $307.55M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $503.97M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |